Source: Health Products Regulatory Authority (IE) Revision Year: 2022 Publisher: Teva B.V., Swensweg 5, 2031GA Haarlem, Netherlands
Nasobec 50 Micrograms Aqueous Nasal Spray.
| Pharmaceutical Form |
|---|
|
Nasal spray, suspension. A white opaque suspension, free from any visible matter. |
Each 100 mg spray contains 50 micrograms beclometasone dipropionate.
Excipients: contains benzalkonium chloride solution 0.02 microlitres.
For a full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Beclometasone |
Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
Nasobec is supplied in polyethylene bottles of 30 ml capacity containing a nominal 200 doses fitted with a metering pump with a built in nasal adaptor. Each bottle is designed to deliver a nominal 100 milligrams of suspension per spray.
Teva B.V., Swensweg 5, 2031GA Haarlem, Netherlands
PA1986/055/001
Date of first authorisation: 04 March 1999
Date of last renewal: 04 March 2009
| Drug | Countries | |
|---|---|---|
| NASOBEC | Hong Kong, Ireland, Malta, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
